Cyclin Dl amplification and expression in human breast carcinoma: Correlation with histological prognostic markers and oestrogen receptor expression

Journal of Clinical Pathology - Clinical Molecular Pathology

Volumn 49, Issue 1, 1996, Pages

  Worsley, S D ^a   Jennings, B A ^a   Khalil, K H ^a   Mole, M ^a   Girling, A C ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Cyclin dl gene; Prognosis

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0030041916     PISSN: 13552910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hunt T. Cyclins and their partners: from a simple idea to a complicated reality. Semin Cell Bwl 1991;2:213-22.
2. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin Dl is a nuclear protein required for cell cycle progression in Gl. Genes Dev 1993;7:812-21.
3. Reed SI. The role of p34 kinases in the Gl to S-phase transition. Annu Rev Cell Bwl 1992;8:529-61.
4. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin Dl protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994; 9:707-18.
5. Jiang W, Khan SM, Zhou P, Zhang YJ, Cacace AM, Infante AS. Overexpression of cyclin Dl in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993;8:3447-57.
6. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin Dl induction in breast cancer cells shortens Gl and is sufficient for cells arrested in Gl to complete the cell cycle. Proc Katl Acad Sei USA 1994;91:8022-6.
7. Arnold A, Kirn HG, Gaz RD, Eddy RL, Fukusima Y, Kronenberg HM. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989; 83:2034-40.
8. Lammie GA, Fantl V, Smith R. D11S287, a putative oncogene on chromosome Ilql3, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991;6:439-44.
9. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8: 2127-33.
10. Lovec H, Sewing A, Lucibello F, Muller R, Moroy T. Oncogenic activity of cyclin Dl revealed through co-operation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 1994;9:323-6.
11. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Nad Acad Sei USA 1991;88:9638-42.
12. Komatsu H, lida S, Yamamoto K, Mikuni C, Nitta M, Takahashi T, et al. A variant chromosome translocation at Ilql3 identifying PRADl/Cyclin Dl as the BCL-1 gene. Blood 1994;84:1226-31.
13. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Centrocytic lymphoma: a B-cell non-Hodgkin's lymphoma characterized by chromosome 11 bcl-1 and PRAD 1 rearrangements. Curr Top Micmbiol Immunol 1992;182: 325-9.
14. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in oesophageal cancer. Cancer Res 1992;52:2980-3.
15. Yoshida T, Sakamoto H, Terada M. Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 1993; 4:33-40.
16. Brookes S, Lammie GA, Schuuring E, Dickson C, Peters G. Linkage map of a region of human chromosome band Ilql3 amplified in breast and squamous cell tumors. Genes Chromosom Cancer 19924:290-301.
17. Klijanienko J, Bianchi AB, Cvitkovic E, Janot F, Luboinsk B, Conti CJ. Unexpected Prad-1 amplification in multiple simultaneous localisations of squamous cell carcinoma of the head and neck [letter]. EurJCancer 1993;29A:653-4.
18. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, et al. Association of parathyroid tumours in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N EnglJ Med 1989;321:218-24.
19. lida S, Seto M, Yamamoto K, Ueda R. Overexpression of PRAD 1 gene in B-cell malignancy with t( 11 ; 14) (q 13 ;q32) translocation. Nippon Rinsho 1992;50:1374-9.
20. Seto M, Yamamoto K, lida S. Gene rearrangement and Overexpression of PRAD1 in lymphoid malignancy with t(ll;14)(ql3;q32) translocation. Oncogene 1992;7:1401-6.
21. Dickson C, Fand V, Gillett C, Brookes S, Bartek J, Smith R, et al. Amplification of chromosome band Ilql3 and a role for cyclin Dl in human breast cancer. Cancer Lett 1995;90:43-50.
22. Lammie GA, Peters G. Chromosome Ilql3 abnormalities in human cancer. Cancer Cells 1991;3:413-19.
23. Fand V, Richards MA, Smith R. Gene amplification on chromosome band Ilql3 and oestrogen receptor status in breast cancer. EurJ Cancer 1990;26:423-9.
24. Champeme MH, Bieche I, Lizard S, Lidereau R. Ilql3 amplification in local recurrence of human primary breast cancer. Genes Chromosom Cancer 199512:128-33.
25. Schuuring E, Verhoeven E, van-Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, et al. Amplification of genes within the chromosome Ilql3 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1992;52:5229-34.
26. Borg A, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Olsson H, et al. Association of INT2/HST1 co-amp-lification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 1991 ; 63:136-42.
27. Henry JA, Hennessy C, Levett DL, Lennard TW, Westley BR, May FE. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc. Int J Cancer 1993;53: 774-80.
28. Tanigami A, To kino T, Takita K, Ueda M, Kasumi F, Nakamura Y. Detailed analysis of an amplified region at chromosome Ilql3 in malignant tumors. Genomics 1992; 13:21-4.
29. Lidereau R, Callahan R, Dickson C, Peters G, Escot C. Amplification of the int-2 gene in primary human breast tumours. Oncogem Res 1988;2:285-91.
30. Goldfarb M, Deed R, MacAllan D, Walther W, Dickson C, Peters G. Chromosomal localisation of the hst oncogene and its co-amplication with the int-2 oncogene in a human melanoma. Oncogene 1988;2:413-16.
31. Brookes S, Lammie GA, Schuuring E, de Boer C, Michalides R, Dickson C, et al. Amplified region of chromosome band Ilql3 on breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1. Genes Chromosom Cancer 1993;6:222-31.
32. Saint-Ruf C, Malfoy B, Scholl S, Zafrani B, Dutrillaux B. GST pi gene is frequently co-amplified with INT2 and HSTF1 proto-oncogenes in human breast cancers. Oncogem 1991;6:403-6.
33. Gillett C, Fand C, Smith R, Fisher C, Bartek J, Dickson C, et al. Amplification and overexpression of cyclin D l in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-17.
34. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503-7.
35. Feinberg AP, Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1984;137:266-72.
36. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues. J Clin Pathol 1994;173:371-9.
37. Escot C, Theillet C, Lidereau R. Genetic alteration of the cmyc proto-oncogene in human primary breast carcinomas. Proc NatlAcadSci USA 1986;83:4834-64.
38. Zhang SY, Camamano J, Cooper F, Klein-stzanto A. Immunohistochemistry of cyclin D l in human breast cancer. Am J Clin Pathol 1994;102:695-8.
39. Brown M. Estrogen receptor molecular biology. Hematol Oncol Clin North Am 1994;8:101-11.
40. Herber B, Truss M, Beato M, Muller R. Inducible regulatory elements in the human cyclin Dl promoter. Oncogene 1994;9:1295-304.
41. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, et al. A truncated cyclin Dl gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 1994;9:1925-9.